Natasha Fay Thoren - May 20, 2025 Form 4 Insider Report for X4 Pharmaceuticals, Inc (XFOR)

Role: Chief Legal Officer
Signature: /s/ Adam S. Mostafa, attorney-in-fact
Stock symbol: XFOR
Transactions as of: May 20, 2025
Transactions value $: $0
Form type: 4
Date filed: 7/3/2025, 04:21 PM
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Thoren Natasha Fay	Chief Legal Officer	C/O X4 PHARMACEUTICALS INC., 61 NORTH BEACON STREET 4TH FLOOR, BOSTON	/s/ Adam S. Mostafa, attorney-in-fact	2025-07-03	0002070977

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	XFOR	Common Stock	Award	$0	+3.33K	+54.38%	$0.00	9.46K	May 20, 2025	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Grant of restricted stock units to the Reporting Person under the Issuer's Amended and Restated 2017 Equity Incentive Plan with each restricted stock unit representing the right to receive one share of common stock on the applicable vesting date. No amount was paid upon the grant of the restricted stock units. The restricted stock units vest in three equal annual installments on May 10, 2026, May 10, 2027 and May 10, 2028, subject to the Reporting Person continuing to provide service as an employee of the Issuer through such date.
F2	The reported amount has been adjusted to reflect a correction to the number of shares beneficially owned by the Reporting Person, which was inadvertently overstated by 855 shares on the Form 3 filed on June 3, 2025.

Content

Grant of restricted stock units to the Reporting Person under the Issuer's Amended and Restated 2017 Equity Incentive Plan with each restricted stock unit representing the right to receive one share of common stock on the applicable vesting date. No amount was paid upon the grant of the restricted stock units. The restricted stock units vest in three equal annual installments on May 10, 2026, May 10, 2027 and May 10, 2028, subject to the Reporting Person continuing to provide service as an employee of the Issuer through such date.

The reported amount has been adjusted to reflect a correction to the number of shares beneficially owned by the Reporting Person, which was inadvertently overstated by 855 shares on the Form 3 filed on June 3, 2025.